Equity
Total Liabilities & Equity
Kailera Therapeutics Total Liabilities & Equity decreased by 9.8% to $624.76M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryOther
SignalHigher is better
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
Growth in this figure generally indicates an expansion of the company's asset base and operational scale.
Detailed definition
This is the sum of all financial obligations and shareholder equity, which must mathematically equal total assets. It re...
Peer comparison
Standard balance sheet total; used as a denominator for various leverage and efficiency ratios across all industries.
Metric ID:
total_liabilities_and_equityHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $692.29M | $624.76M |
| QoQ Change | — | -9.8% |
Range$624.76M – $692.29M
Total Liabilities & Equity at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's total liabilities & equity?
- Kailera Therapeutics (KLRA) reported total liabilities & equity of $624.76M in Q1 2026.
- What does total liabilities & equity mean?
- The total amount of funding the company has received from both creditors and shareholders.